Milestone Scientific’s Q1 2025 Revenue Highlights
Milestone Scientific Inc. (NYSE: MLSS), a pioneer in the development of innovative computerized drug delivery systems, recently unveiled its business performance for the first quarter of 2025, reporting revenues that reached approximately $2.2 million. This figure signifies a small year-over-year decline of about $16,000, yet it underscores the company’s commitment to enhancing its areas of focus.
Growing Demand in the Medical Segment
Chairman’s Insights on Progress
Neal Goldman, Chairman and Interim CEO, expressed optimism regarding the company’s response within its medical segment. The first quarter exhibited increased traction with the CompuFlo® Epidural System. Notably, new medical practices have begun to integrate this technology into their procedures, which reflects the growing recognition of CompuFlo’s ability to improve patient safety and procedural efficacy. The positive feedback from practices highlights the potential of this technology as a significant resource in pain management.
Expanding Medicare Reach
Milestone Scientific is actively working to broaden its acceptance within existing Jurisdictional Medicare Administrative Contractors (JMACs). The company aims to enhance regional penetration while engaging additional JMACs and their advisory boards. A crucial aspect of this expansion is the favorable Medicare Part B physician payment rates assigned to the CompuFlo technology, which have been set under CPT code 0777T. This reimbursement structure is anticipated to facilitate greater access and adoption in the coming periods.
Federal Healthcare Initiatives
Contract Award Under Federal Supply Schedule
In an effort to boost the adoption of CompuFlo within federal healthcare scenarios, Milestone Scientific secured a contract under the Federal Supply Schedule (FSS). This contract enables U.S. government medical entities to procure CompuFlo systems, paving the way for collaborations with influential federal healthcare system bodies. The focus now moves towards promoting this technology within departments such as Veterans Affairs (VA), the Department of Defense (DoD), and the Indian Health Service (IHS), representing a significant stride in enhancing patient care across various federal health facilities.
Dental Business Stability and Financial Management
Steady Performance in Dental Services
Despite some fluctuations in their medical sector revenues, Milestone Scientific reported steady performance in its dental division during this quarter. The company has adopted a strategic approach to financial management, prioritizing cost containment and deferring non-essential research and development expenditures as needed.
Securing Convertible Financing
Moreover, during this period, Milestone Scientific obtained $800,000 in convertible financing from its board members, including Goldman himself. This financing comes with favorable terms, including a below-market interest rate, reinforcing the belief in the company’s growth potential and its strategic plans moving forward.
Financial Overview for Q1 2025
The financial snapshot of Milestone Scientific for the first quarter of 2025 indicates that international revenues amounted to approximately $863,000, down $67,000 from the previous year. Notably, revenues from medical services surged to approximately $51,000, up from $7,400 in Q1 2024, marking a significant increase. Overall, while the company reported a gross profit of $1.6 million, reflecting a 74% margin, operating losses amounted to approximately $2.0 million, showing a slight increase compared to losses in 2024.
Conclusion and Future Directions
As the company positions itself for future growth, the emphasis on expanding its reimbursement framework and broadening its market presence is evident. With a strategic focus on key sectors and ongoing collaborations, Milestone Scientific is paving a robust path forward, seeking to foster long-term value for its shareholders while enhancing the health sector through its innovative technologies.
Frequently Asked Questions
What were Milestone Scientific's total revenues for Q1 2025?
Milestone Scientific reported total revenues of approximately $2.2 million for the first quarter of 2025.
What is the significance of CPT code 0777T for Milestone Scientific?
CPT code 0777T is significant as it provides a favorable Medicare Part B physician payment rate for Milestone Scientific's CompuFlo technology, encouraging wider adoption.
How did the medical segment perform for Milestone Scientific?
The medical segment showed increased momentum, particularly with the CompuFlo Epidural System, leading to new practice integrations.
What financing opportunities has Milestone Scientific pursued recently?
Milestone Scientific secured $800,000 in convertible financing from its Board of Directors, demonstrating confidence in the company's growth strategy.
What is the future outlook for Milestone Scientific?
Milestone Scientific is optimistic about expansion efforts in both the medical and dental markets, focusing on reimbursement frameworks and nurturing partnerships within federal healthcare systems.
